Treace Medical Concepts (TMCI) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TMCI shares.
View TMCI analyst ratings or view top-rated stocks.

5 analysts have issued 1 year price targets for Treace Medical Concepts' shares. Their TMCI share price forecasts range from $26.00 to $33.00. On average, they predict the company's share price to reach $29.60 in the next year. This suggests a possible upside of 12.8% from the stock's current price.
View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts.

Treace Medical Concepts' stock was trading at $22.99 on January 1st, 2023. Since then, TMCI shares have increased by 14.1% and is now trading at $26.24.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our TMCI earnings forecast.

Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced its earnings results on Monday, May, 8th. The company reported ($0.23) EPS for the quarter, meeting analysts' consensus estimates of ($0.23). The firm earned $42.20 million during the quarter, compared to analyst estimates of $39.48 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 48.57% and a negative net margin of 30.48%.

ETFs with the largest weight of Treace Medical Concepts (NASDAQ:TMCI) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), iShares U.S. Medical Devices ETF (IHI),

Treace Medical Concepts updated its FY 2023 earnings guidance on Monday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $190.00 million-$196.00 million, compared to the consensus revenue estimate of $190.54 million.

(TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."

Treace Medical Concepts' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.24%), Perceptive Advisors LLC (3.99%), Next Century Growth Investors LLC (2.51%), CIBC Private Wealth Group LLC (2.30%), Emerald Advisers LLC (2.23%) and Emerald Mutual Fund Advisers Trust (1.83%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends.

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TMCI stock can currently be purchased for approximately $26.24.

Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $1.61 billion and generates $141.84 million in revenue each year. The company earns $-42,810,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

The company employs 248 workers across the globe.

Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net.